ARCELLX INC (ACLX) Fundamental Analysis & Valuation

NASDAQ:ACLX • US03940C1009

114.36 USD
+0.06 (+0.05%)
At close: Mar 5, 2026
114.36 USD
0 (0%)
After Hours: 3/5/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ACLX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, ACLX scores 3 out of 10 in our fundamental rating. ACLX was compared to 520 industry peers in the Biotechnology industry. While ACLX has a great health rating, there are worries on its profitability. ACLX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. ACLX Profitability Analysis

1.1 Basic Checks

  • ACLX had negative earnings in the past year.
  • In the past year ACLX has reported a negative cash flow from operations.
  • In the past 5 years ACLX always reported negative net income.
  • In the past 5 years ACLX reported 4 times negative operating cash flow.
ACLX Yearly Net Income VS EBIT VS OCF VS FCFACLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M

1.2 Ratios

  • ACLX has a Return On Assets (-37.90%) which is comparable to the rest of the industry.
  • ACLX has a better Return On Equity (-56.90%) than 61.54% of its industry peers.
Industry RankSector Rank
ROA -37.9%
ROE -56.9%
ROIC N/A
ROA(3y)-20.52%
ROA(5y)-34.43%
ROE(3y)-31.69%
ROE(5y)-49.03%
ROIC(3y)N/A
ROIC(5y)N/A
ACLX Yearly ROA, ROE, ROICACLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • ACLX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACLX Yearly Profit, Operating, Gross MarginsACLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ACLX Health Analysis

2.1 Basic Checks

  • ACLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ACLX has more shares outstanding
  • The number of shares outstanding for ACLX has been increased compared to 5 years ago.
  • There is no outstanding debt for ACLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACLX Yearly Shares OutstandingACLX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
ACLX Yearly Total Debt VS Total AssetsACLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 17.57 indicates that ACLX is not in any danger for bankruptcy at the moment.
  • ACLX has a Altman-Z score of 17.57. This is amongst the best in the industry. ACLX outperforms 87.88% of its industry peers.
  • ACLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.57
ROIC/WACCN/A
WACC8.73%
ACLX Yearly LT Debt VS Equity VS FCFACLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • ACLX has a Current Ratio of 4.44. This indicates that ACLX is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 4.44, ACLX perfoms like the industry average, outperforming 51.35% of the companies in the same industry.
  • ACLX has a Quick Ratio of 4.44. This indicates that ACLX is financially healthy and has no problem in meeting its short term obligations.
  • ACLX has a Quick ratio (4.44) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.44
Quick Ratio 4.44
ACLX Yearly Current Assets VS Current LiabilitesACLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ACLX Growth Analysis

3.1 Past

  • The earnings per share for ACLX have decreased strongly by -103.50% in the last year.
  • The Revenue for ACLX has decreased by -79.35% in the past year. This is quite bad
EPS 1Y (TTM)-103.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.09%
Revenue 1Y (TTM)-79.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-89.17%

3.2 Future

  • Based on estimates for the next years, ACLX will show a very strong growth in Earnings Per Share. The EPS will grow by 29.30% on average per year.
  • ACLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 99.45% yearly.
EPS Next Y6.35%
EPS Next 2Y14.58%
EPS Next 3Y21.97%
EPS Next 5Y29.3%
Revenue Next Year178.11%
Revenue Next 2Y164.4%
Revenue Next 3Y140.17%
Revenue Next 5Y99.45%

3.3 Evolution

ACLX Yearly Revenue VS EstimatesACLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
ACLX Yearly EPS VS EstimatesACLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. ACLX Valuation Analysis

4.1 Price/Earnings Ratio

  • ACLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACLX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACLX Price Earnings VS Forward Price EarningsACLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACLX Per share dataACLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ACLX's earnings are expected to grow with 21.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.58%
EPS Next 3Y21.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ACLX Dividend Analysis

5.1 Amount

  • ACLX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACLX Fundamentals: All Metrics, Ratios and Statistics

ARCELLX INC

NASDAQ:ACLX (3/5/2026, 8:00:01 PM)

After market: 114.36 0 (0%)

114.36

+0.06 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners99.7%
Inst Owner Change-1.21%
Ins Owners1.19%
Ins Owner Change-1.51%
Market Cap6.69B
Revenue(TTM)22.29M
Net Income(TTM)-228.93M
Analysts68.33
Price Target112.44 (-1.68%)
Short Float %18.87%
Short Ratio4.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.49%
Min EPS beat(2)4.54%
Max EPS beat(2)8.44%
EPS beat(4)3
Avg EPS beat(4)-5.96%
Min EPS beat(4)-46.25%
Max EPS beat(4)9.43%
EPS beat(8)5
Avg EPS beat(8)-0.9%
EPS beat(12)6
Avg EPS beat(12)-6.33%
EPS beat(16)7
Avg EPS beat(16)-20.54%
Revenue beat(2)0
Avg Revenue beat(2)-70.13%
Min Revenue beat(2)-87.9%
Max Revenue beat(2)-52.37%
Revenue beat(4)0
Avg Revenue beat(4)-61.53%
Min Revenue beat(4)-87.9%
Max Revenue beat(4)-45.6%
Revenue beat(8)2
Avg Revenue beat(8)-25.59%
Revenue beat(12)3
Avg Revenue beat(12)-5.51%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.88%
PT rev (3m)-1.13%
EPS NQ rev (1m)-1.08%
EPS NQ rev (3m)-0.47%
EPS NY rev (1m)-0.13%
EPS NY rev (3m)-1.7%
Revenue NQ rev (1m)4.39%
Revenue NQ rev (3m)-12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-25.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 300.09
P/FCF N/A
P/OCF N/A
P/B 16.62
P/tB 16.62
EV/EBITDA N/A
EPS(TTM)-4.07
EYN/A
EPS(NY)-3.81
Fwd EYN/A
FCF(TTM)-3.64
FCFYN/A
OCF(TTM)-3.6
OCFYN/A
SpS0.38
BVpS6.88
TBVpS6.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -37.9%
ROE -56.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.52%
ROA(5y)-34.43%
ROE(3y)-31.69%
ROE(5y)-49.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.85%
Cap/Sales 10.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.44
Quick Ratio 4.44
Altman-Z 17.57
F-Score2
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)448.06%
Cap/Depr(5y)414.54%
Cap/Sales(3y)14.1%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-103.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.09%
EPS Next Y6.35%
EPS Next 2Y14.58%
EPS Next 3Y21.97%
EPS Next 5Y29.3%
Revenue 1Y (TTM)-79.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-89.17%
Revenue Next Year178.11%
Revenue Next 2Y164.4%
Revenue Next 3Y140.17%
Revenue Next 5Y99.45%
EBIT growth 1Y-83.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.48%
EBIT Next 3Y22.7%
EBIT Next 5Y27.46%
FCF growth 1Y-119.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-151.91%
OCF growth 3YN/A
OCF growth 5YN/A

ARCELLX INC / ACLX FAQ

What is the fundamental rating for ACLX stock?

ChartMill assigns a fundamental rating of 3 / 10 to ACLX.


What is the valuation status for ACLX stock?

ChartMill assigns a valuation rating of 1 / 10 to ARCELLX INC (ACLX). This can be considered as Overvalued.


Can you provide the profitability details for ARCELLX INC?

ARCELLX INC (ACLX) has a profitability rating of 1 / 10.


Can you provide the financial health for ACLX stock?

The financial health rating of ARCELLX INC (ACLX) is 7 / 10.